Table 2 Clinical and tumor characteristics of the whole patient cohort before TACE treatment according to BCLC tumor stage
From: TACE performed in patients with a single nodule of Hepatocellular Carcinoma
Variable | BCLC-0 (n = 16) | BCLC-A (n = 104) | BCLC-B (n = 13) | BCLC-C (n = 15) |
|---|---|---|---|---|
Within Milan Criteria, n (%) * | 16 (100) | 104 (100) | 0 | 15 (100) |
Tumor size, median (cm) (range) | 1.3 (1.0 – 1.9) | 3.0 (0.8 – 5.0) | 6.0 (5.1 – 15.0) | 3.0 (1.0 – 4.8) |
Portal vein thrombosis, n (%) | ||||
Absent | 14 (88) | 94 (90) | 11 (85) | 12 (80) |
Segmental bland thrombosis | 0 | 3 (3) | 0 | 1 (7) |
Lobar bland thrombosis | 2 (12) | 7 (7) | 2 (15) | 2 (13) |
Hepatic function pre TACE, n (%) | ||||
CPT-A | 16 (100) | 58 (56) | 8 (62) | 10 (67) |
CPT-B | 0 | 46 (44) | 5 (38) | 5 (33) |
Performance status pre TACE, n (%) | ||||
0 | 16 (100) | 104 (100) | 13 (100) | 0 |
1 | 0 | 0 | 0 | 15 (100) |